Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790024 | 0.99 | ABCG2 (0.71) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8788465 | 0.97 | ABCG2 (0.72) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8790060 | 0.97 | ABCG2 (0.72) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8789970 | 0.97 | ABCG2 (0.70) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8789266 | 0.95 | ABCG2 (0.72) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8789555 | 0.95 | ABCG2 (0.77) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8789900 | 0.91 | ABCG2 (0.68) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8789922 | 0.90 | ABCG2 (0.55) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8789610 | 0.89 | ABCG2 (0.66) | ABCG2ABCB1LMNAL3MBTL1MEN1 | |
| SCHEMBL8790230 | 0.89 | ABCG2 (0.66) | ABCG2ABCB1LMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |